The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia

Not Applicable

Recruiting

• Conditions: Hyperuricemia
• Interventions: Dietary Supplement: Study Product A (High-dose 2X); Dietary Supplement: Placebo; Dietary Supplement: Study Product B (Low-dose X)

• Registration Number: NCT06084585
• Lead Sponsor: Amway (China) R&D Center

Brief Summary

The goal of this three arms, randomized, double-blind controlled interventional study is to evaluate the efficacy of Amway uric acid lowering product improving hyperuricemia in patients aged 18 and 65 years old. The main question it aims to answer is:

- whether the serum uric acid level of patients with hyperuricemia could be significantly lowered after 3 months intervention with Amway uric acid lowering product

180 eligible participants will be enrolled in one study site and randomized to three study groups (two product group and one placebo group), who will consume the assigned products for 3 months and be arranged to 3 site visits. All relevant clinical data will be captured and recorded into CTMS (Clinical Trial Management System) for statistical analysis and reporting.

Researchers will compare the three study groups to conclude how Amway uric acid lowering product will improve hyperuricemia.

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-10
• Study First Submitted: 2023-10-10
• Study First Submitted QC: 2023-10-10
• Last Update Submitted: 2023-10-10
• Study First Posted: 2023-10-16
• Last Update Posted: 2023-10-16
• Study Start: 2023-10-23
• Primary Completion: 2024-02-28
• Study Completion: 2024-03-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

• Participants aged between 18 and 65 years old (mostly above 35 years old), including male and female and the ratio of male to female is not limited;
• Patients with hyperuricemia: meet the diagnostic criteria set out in the "Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout (2019)", and fasting blood uric acid level exceeds 420 μmol/L twice on different days. Further classification using the Janssens Gout Diagnostic scale included asymptomatic hyperuricemia (that is, never had a gout attack) and patients with a history of gout, with a ratio of about 1:1;
• Participants agree not to take any drugs, supplements, or performance enhancers during the study, or they will be eliminated
• Participants understand the test procedure, read, and sign an appropriate Informed Consent Form indicating their willingness to participate.

Exclusion Criteria

• Secondary gout caused by kidney disease, blood disease, drug use, tumor radiotherapy and chemotherapy;
• Subjects who are using drugs during gout attacks;
• Malignant diseases: patients with severe lung, cardiovascular, blood and hematopoietic system, central nervous system or other system diseases, as well as tumor patients;
• Severe obesity (BMI>32kg/m2);
• Abnormal liver and kidney function: abnormal level of alanine aminotransferase or aspartate aminotransferase; Serum creatinine was higher than the upper limit of the normal range;
• Allergic to the test drug or weak or allergic;
• Pregnant or lactating women or those who have pregnancy plans; Sex hormone replacement therapy and oral contraception in the past 3 months;
• Subjects who have participated in other research projects within three months;
• Subjects that other researchers considered should be excluded.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Study Product A (High-dose 2X)	Study Product A (High-dose 2X)	Amway uric acid lowering product: 5g/sachet, containing the following active ingredients: * Celery seed (functional raw material) * Dasiphora mandshurica (functional raw material) * Cichorium intybus L. (functional raw material) * Lotus leaf (functional raw material) * Tart cherry (functional raw material) * γ-cyclodextrin * Erythritol * Silicon dioxide * Resistant dextrin * Black tea essence
Placebo	Placebo	Placebo product: 5g/sachet, containing the following active ingredients: * Maltodextrin * Pigment * Erythritol * Bitters * Essence of flavor
Study Product B (Low-dose X)	Study Product B (Low-dose X)	Amway uric acid lowering product: 5g/sachet, containing the following active ingredients: * Celery seed (functional raw material) * Dasiphora mandshurica (functional raw material) * Cichorium intybus L. (functional raw material) * Lotus leaf (functional raw material) * Tart cherry (functional raw material) * γ-cyclodextrin * Erythritol * Silicon dioxide * Resistant dextrin * Black tea essence

Primary Outcome Measures

Name	Time	Method
Change of Serum Uric Acid Level	baseline, and 12 weeks	Change of Serum Uric Acid Level from baseline to 12 weeks, in unit of μmol/L, diagnosed as hyperuricemia if the level exceeds 420umol/L twice on different days

Secondary Outcome Measures

Name	Time	Method
Change of Serum Uric Acid Level	baseline, and 6 weeks	Change of Serum Uric Acid Level from baseline to 6 weeks, in unit of μmol/L, diagnosed as hyperuricemia if the level exceeds 420umol/L twice on different days
Fractional Excretion of Uric Acid (FEUA)	baseline, 6 weeks, and 12 weeks	Fractional Excretion of Uric Acid (FEUA), defined as the percentage of urate filtered by glomeruli that is excreted in urine, normal range 7\~12%. A FEUA value less than 7% considered low, indicating decreased renal excretion of uric acid. A FEUA value above 12% is considered high, suggesting increased renal excretion of uric acid.

Trial Locations

Locations (1)

Charlie Zhang; 🇨🇳 Jinhua, Zhejiang, China